Citations

Clear

4510 citation(s) found for "Scott, C".

Recommendations for the Deprescribing of Psychotropic Medications
Goldberg, Joseph F. , McIntyre, R. S., Freeman, Marlene P. , Mago, Rajnish, Citrome, Leslie, Rosenblat, Joshua D., Thase, Michael E., Tohen, Mauricio, Vieta, Eduard, Malhi, Gin S, Sajatovic, M., Shelton, Richard C. , Macaluso, Matthew , Berk, Michael, Perlis, Roy H., Ostacher, Michael J., Khan, Arifulla, Sanacora, Gerard , Kane, John M., D, Goodman, Nierenberg, Andrew A., Correll, Christoph U., Kupka, R. W., Kasper, Siegfried, Furukawa, Toshi A., Davis, Lori L., Aaronson, Scott T., Gitlin, Michael , Jha, Manish K., Cohen, Lawrence J. , Papakostas, George I. , Mitchell, Philip B., Gorwood, P., Gupta, Swapnil , Frye, Mark A., Young, A. H., Zohar, Joseph, Steingard, Sandra , Zarate, Carlos A., Clayton, Anita H. , Shelton, Richard C. , Young, Allan H. , Ostacher, Michael J. , Jha, Manish K. , Young, Allan H , Jha, Manish K , Ostacher, Michael J , McIntyre, Roger S. , Swartz, Holly A. , Citrome, Leslie , Rosenblat, Joshua D. , Thase, Michael E. , Tohen, Mauricio , Vieta, Eduard , Malhi, Gin S. , Sajatovic, Martha, Berk, Michael , Perlis, Roy H , Iosifescu, Dan Vlad , Rubio, Jose M , Kane, John M. , Nierenberg, Andrew A. , Correll, Christoph Ulrich , Kupka, Ralph , Kasper, Siegfried , Furukawa, Toshi A , Aaronson, Scott T. , Mitchell, Philip B , Gorwood, Philip , Frye, Mark A. , Zohar, Joseph , Zarate, Carlos A.

Mayo Clinic

JAMA Network Open | February 25, 2026 | Volume: 9 | Issue: 2 | Pages: e260043

10.1001/jamanetworkopen.2026.0043 | PMID 41739481 Get It

Importance There is a need for greater recognition of clinical psychopharmacology endpoints, including instances where specific psychotropic medications may become unnecessary, redundant, contradictory, or otherwise inappropriate and therefore merit deprescribing. Objective To address circumstances warranting psychotropic medication deprescribing. Evidence Review The American Society of Clinical Psychopharmacology convened a panel of 45 international psychopharmacology experts who developed and completed a multiround Delphi survey and conducted a focused literature review between January and May of 2025, in order to identify areas of consensus or disagreement on key aspects of the deprescribing of psychotropic medications. These included collaborative risk-benefit assessments with patients; pharmacokinetic and pharmacodynamic factors; pharmacogenomics; distinguishing redundant or conflictual from complementary mechanisms of action; managing adverse effects; assuring medication adherence; drug tolerance or tachyphylaxis; medication misuse; and the psychological context and ramifications of deprescribing. Findings Consensus was achieved on 44 of 50 final Delphi statements (88%). Panelists unanimously agreed that components of a pharmacotherapy regimen should undergo periodic review to ensure that treatments target relevant symptoms and have favorable risk-benefit ratios. Key points of consensus were that deprescribing: (1) should not occur without first assessing medication adherence; (2) merits consideration if less than partial therapeutic response is apparent, or if treatment goals have been reached and relapse prevention is not a long-term objective; (3) involves psychological ramifications that warrant attention; (4) should be followed by close clinical monitoring; and (5) risk-benefit decisions should ideally involve active patient participation within a shared decision-making model. Conclusions and Relevance Through this Consensus Statement, the Task Force identified circumstances in which the selective elimination of certain psychotropic medications may be clinically indicated. Empirical trials are needed to assess the implementation of deprescribing protocols and gauge their safe, effective, and acceptable outcomes.
SARS-CoV-2 infects human primary cytotrophoblasts mainly through a non-canonical entry route
Pinatel, Hélène, Brien, Marie‐Eve , Broquière, Mathilde , Scott-Boyer, Marie-Pier, Droit, Arnaud , Girard, Sylvie, Chatel‐Chaix, Laurent , Vaillancourt, Cathy , Girard, Sylvie , Sylvie, Girard , Chatel-Chaix, Laurent , Vaillancourt, Cathy , Scott‐Boyer, Marie‐Pier , Delbès, Géraldine

Mayo Clinic

Molecular Human Reproduction | February 25, 2026 | Volume: 32 | Issue: 1 | Pages: No page available

10.1093/molehr/gaag015 | PMID 41755626 Get It

Abstract Since the beginning of the COVID-19 pandemic, vulnerable populations such as pregnant persons have been at higher risk of severe symptoms and poor outcomes. Although reports of SARS-CoV-2 vertical transmission remain rare, several studies showed that maternal infection during pregnancy can induce histomorphological and inflammatory alterations in the placenta. However, the permissiveness of human trophoblasts to various variants of the virus remains poorly characterized. In this study, human primary villous cytotrophoblasts isolated from term placentas, along with trophoblastic cell lines BeWo, JEG-3, and HIPEC-65 were infected with the ancestral SARS-CoV-2 strain, which disseminated worldwide in early 2020. Permissiveness was assessed with quantitative RT-PCR, immunostaining of viral protein Nucleocapsid, and plaque assays. To investigate viral entry routes, cells were treated with Camostat mesylate (an inhibitor of the co-entry factor TMPRSS2) or chloroquine phosphate (an endosomal entry inhibitor) and viral fitness was assessed by plaque assays. Primary villous cytotrophoblasts and JEG-3 cells were also tested for infection with three pre-omicron SARS-CoV-2 variants of concern. Our results show that primary villous cytotrophoblasts are permissive to all tested SARS-CoV-2 strains in vitro. Infection with the ancestral SARS-CoV-2 strain relies mainly on a non-canonical endosomal entry pathway. Notably, JEG-3 cells represent an appropriate and convenient model for studying trophoblast infection by SARS-CoV-2, as they exhibit high permissiveness to the ancestral strain, and the SARS-CoV-2 entry pathway is similar to that in villous cytotrophoblasts. Overall, this study reveals that the cytotrophoblastic permissiveness to SARS-CoV-2 depends on the viral genetic nature and provides new insights into its entry route in human trophoblasts.
Variation in Lipid Management for Atherosclerotic Cardiovascular Disease Across US Health Systems
Shah, Nishant , Peterson, Eric D. , Shrader, Peter, Shoji, Satoshi , Freeman, Nikki , Martin, Seth S., Allred, Clint, Fernandez, S. A., Chamberlain, Alanna M., Arnold, Jonathan , Shapiro, Michael D., Priest, Elisa L. , Syed, Mahanaz, Kirchner, H. Lester , Leja, Monika, Kalich, Bethany , Jin, Ran , Navar, Ann Marie, Peterson, Eric D. , Chamberlain, Alanna M. , Arnold, Jonathan , Shah, Nishant P , Martin, Seth S , Fernandez, Soledad , Chamberlain, Alanna M , Shapiro, Michael D , Effron, Mark B , Syed, Mahanaz , Kirchner, H Lester , Kalich, Bethany , Jin, Ran , Wojcik, Cezary , Navar, Ann Marie , Shrader, Peter, Martin, Seth S. , Ahmad, Zahid , Jones, Laney K , Návar, Ann Marie

Mayo Clinic

Circulation: Population Health and Outcomes | February 20, 2026 | Volume: 19 | Issue: 4 | Pages: No page available

10.1161/circoutcomes.125.012622 | PMID 41717695 Get It

BACKGROUND: While health systems have implemented resources to improve lipid management in people with atherosclerotic cardiovascular disease, the population-level effectiveness is unclear. METHODS: Electronic health record data from patients with atherosclerotic cardiovascular disease between January 1, 2021, and December 31, 2023, across 16 US academic health systems were analyzed. Atherosclerotic cardiovascular disease (defined by diagnosis and procedure codes) was established on or before the index date defined as the date of the most recent LDL-C (low-density lipoprotein-cholesterol) or the last day of the study period for those without an LDL-C available. Systems were surveyed to identify lipid management programs (eg, prevention/lipid clinic, electronic health record–based tools, and lipid management algorithms). Sequential multilevel multivariable logistic regression modeling was used to (1) assess the system-level association between an LDL-C <70 mg/dL and the presence of lipid management programs, adjusting for patient-level demographic and clinical characteristics, and (2) whether system-level uptake of statin or nonstatin lipid-lowering therapy was associated with an LDL-C <70 mg/dL. RESULTS: We included 1 738 042 patients with atherosclerotic cardiovascular disease (median, 88 365 per system; range, 17 086–2 48 371). About 81% of the health systems had prevention or lipid clinics. The proportion of those on statins ranged from 31.0% to 60.4% across health systems (median, 46.3%). Lower proportions were observed in the use of high-intensity statins (16.2%–33.1%), nonstatins (2.6%–8.1%), and combination lipid-lowering therapy (1.7%–6.3%). Among those with an LDL-C level available (n=890 521), 42.5% had an LDL-C <70 mg/dL, ranging 35.8% to 49.4% across systems. There was no association between the odds of achieving LDL-C <70 mg/dL and health system lipid management algorithm, prevention clinics/lipid clinics, or electronic health record–based tools. Neither system-level high-intensity statin utilization nor nonstatin use was associated with an LDL-C <70 mg/dL. CONCLUSIONS: Despite variability in lipid management resources and lipid-lowering therapy use across systems, many did not reach an LDL-C <70 mg/dL, and there was low uptake of lipid-lowering therapy. Innovative implementation strategies are needed for system-level lipid management.
Prognostic Significance of Prolonged QTc Interval in Patients on Dialysis: A Retrospective Cohort Study
Pham, Hoang Nhat, Ibrahim, R, Giauque, Nathan A., Mahmoud, Ahmed K., Dreher, Luke, Scott, Luis R., Ayoub, Chadi, Arsanjani, Reza, LeMond, Lisa , Singh, Amitoj, Sorajja, Dan , Ayoub, Chadi , Ayoub, Chadi , Pham, Hoang Nhat , Giauque, Nathan Anthony, Mahmoud, Ahmed K , Dreher, Luke , Scott, Luis R. , Arsanjani, Reza , Singh, Amitoj

Mayo Clinic

Journal of Arrhythmia | February 19, 2026 | Volume: 42 | Issue: 1 | Pages: No page available

10.1002/joa3.70299 | PMID 41727701 Get It

ABSTRACT Background Prolonged QT interval is common in end‐stage renal disease (ESRD) on dialysis, but its long‐term cardiovascular (CV) implications remain unclear. Methods Using TriNetX network (2010–2024), we identified adults with ESRD on dialysis and categorized them by QTc status. After 1:1 propensity score matching ( n = 3428/group), outcomes (hazard ratio [HR]) were assessed using Cox regression. Results Prolonged QTc (> 500 ms) was associated with higher risk of all‐cause mortality (HR 1.67; p < 0.001), MACEs (HR 1.40; p < 0.001), cardiac arrest (HR 1.75; p < 0.001), sustained ventricular arrhythmia (HR 1.66; p < 0.001), new‐onset atrial fibrillation (HR 1.12; p = 0.01), and acute myocardial infarction (HR 2.19; p < 0.001). Conclusions In ESRD patients on dialysis, prolonged QT interval was independently associated with adverse CV outcomes and mortality.
Continuous At-Home Monitoring of Nighttime Bed Behavior in Frontotemporal Dementia
Paolillo, Emily W., Wise, Amy, Kaye, Jeffrey A., Beattie, Zachary , Dhanam, Sreya, Casaletto, Kaitlin B. , Saloner, Rowan, Mendez, Mario F., Vandevrede, Lawren, Ljubenkov, Peter A. , Seeley, William W., Gorno-Tempini, Maria Luisa, Miller, Bruce L., Heuer, Hilary W. , Forsberg, Leah K., Kornak, John , Boeve, Bradley F., Boxer, Adam L., Rosen, Howard J., Walsh, Christine M., Staffaroni, Adam M., Abdullah, Muhammad, Apostolova, Liana , Ece, Bayram, Botha, Hugo, Brushaber, Danielle , Clark, David, Considine, Ciaran , Darby, R. Ryan , Day, Gregory S., Dickerson, Bradford, Dickson, Dennis, Domoto-Reilly, Kimiko, Dwosh, Emily , Faber, Kelley , Fagan, Anne M. , Fields, Julie A. , Fong, Jamie C., Foroud, Tatiana M., Galasko, Douglas R., Gavrilova, Ralitza, Gendron, Tania, Geschwind, Daniel, Ghoshal, Nupur , Goldman, Jill, Graff-Radford, Jonathan, Graff-Radford, Neill, Grant, Ian M., Grossman, Murray, Hales, Chadwick M., Hall, Matthew, Honig, Lawrence S., Hsiung, Ging-Yuek (Robin), Huang, Eric S., Huey, Edward D, Irwin, David, Johnson, Noah, Jones, David T., Kantarci, Kejal, Knopman, David, Kolander, Tyler, Kwan, Justin Y., Lago, Argentina Lario , Lapid, Maria, Lavigne, Shannon B., Lee, Suzee, Litvan, Irene, Lucente, Diane , Mackenzie, Ian R., Masdeu, Joseph C. , Massimo, Lauren , McGinnis, Scott, McMillan, Corey T., Mester, Carly, Miyagawa, Toji , Molden, Joie, Onyike, Chiadi, Pascual, Belen, Paulson, Henry, Petrucelli, Leonard, Pressman, Peter, Rademakers, Rosa, Ramanan, Vijay, Ramos, Eliana Marisa , Rankin, Katherine P., Rao, Meghana, Rascovsky, Katya, Rhoads, Kristoffer , Ritter, Aaron, Rogalski, Emily, Rojas, Julio C., Savica, Rodolfo, Snyder, Allison, Sullivan, Anna Campbell, Syrjanen, Jeremy, Tartaglia, M. Carmela, Taylor, Jack, Weintraub, Sandra, Wint, Dylan , Wong, Bonnie, Yokoyama, Jennifer, Mendez, Mario F. , VandeVrede, Lawren , Paolillo, Emily W. , Wise, Amy B. , Saloner, Rowan , Forsberg, Leah Kathleen, VandeVrede, Lawren , Mendez, Mario , Paolillo, Emily W , Kaye, Jeffrey , Au-Yeung, Wan-Tai Michael , Dhanam, Sreya , Seeley, William W. , Gorno‐Tempini, Maria Luisa , Forsberg, Leah K. , Kremers, Walter K. , Boeve, Bradley F. , Boxer, Adam L. , Rosen, Howard J. , Walsh, Christine M. , Staffaroni, Adam M. , Appleby, Brian S. , Barmada, Sami , Bozoki, Andrea C , Domoto‐Reilly, Kimiko , Galasko, Douglas , Gavrilova, Ralitza H. , Gendron, Tania F. , Geschwind, Daniel H., Graff‐Radford, Jonathan , Graff‐Radford, Neill R. , Grossman, Murray, Hales, Chadwick M. , Hall, Matthew , Honig, Lawrence, Hsiung, Ging‐Yuek Robin , Huey, Edward D. , Irwin, David J. , Kantarci, Kejal , Knopman, David, Kwan, Justin , Lavigne, Shannon B., Léger, Gabriel C. , Litvan, Irene , Mackenzie, Ian R. , Masdeu, Joseph C , McMillan, Corey T. , Mester, Carly , Molden, Joie, Pantelyat, Alexander , Pascual, Belén , Petrucelli, Leonard , Pressman, Peter , Rademakers, Rosa, Rankin, Katherine P. , Rao, Meghana , Rascovsky, Katya, Roberson, Erik D. , Rogalskı, Emily , Rojas, Julio C. , Savica, Rodolfo , Snyder, Allison , Syrjanen, Jeremy A. , Tartaglia, Maria Carmela , Taylor, Jack C. , Tipton, Philip W. , Vandebergh, Marijne , Weıntraub, Sandra , Wong, Bonnie

Mayo Clinic

Neurology Open Access | February 18, 2026 | Volume: 2 | Issue: 1 | Pages: No page available

10.1212/wn9.0000000000000068 | PMID 41987885 Get It

Impact of contemporary guideline-directed medical therapy on secondary mitral and tricuspid regurgitation in heart failure with reduced ejection fraction
Naser, Jwan A. , Rahme, Serena, Castrichini, M, Ibrahim, Hossam, Scott, Christopher G, Kennedy, Austin M , Eleid, Mackram F., Nkomo, Vuyisile T, Borlaug, Barry A, Lin, G, Scott, Christopher G. , Nkomo, Vuyisile T. , Borlaug, Barry A. , Rahme, Serena J, Scott, Christopher , Nkomo, Vuyisile T , Foley, David A. , Borlaug, Barry A , Sabbah, Michael S. , Kennedy, Austin M , Naser, Jwan A , Castrichini, Matteo , Ibrahim, Hossam H , Eleid, Mackram F. , McKie, Paul M. , Pislaru, Sorin V.

Mayo Clinic

European Journal of Heart Failure | February 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ejhf/xuag047 | PMID 41771144 Get It

Abstract Aims We aimed to assess regression and development rates of ≥moderate secondary mitral regurgitation (MR) and tricuspid regurgitation (TR) in patients with heart failure and reduced ejection fraction (HFrEF) receiving contemporary guideline-directed medical therapy (GDMT). Methods Patients with a &lt;1 year diagnosis of HFrEF with mildly (40% ≤ EF &lt; 50%) or moderately (&lt;40%) reduced EF enrolled in GDMT titration programme 2019–2024 were identified. Regression rates of ≥moderate MR/TR to ≤mild and development rates of incident ≥moderate MR/TR were calculated. Results Among 844 patients [median age 64; 68% men; 26% mildly reduced EF; 24% New York Heart Association (NYHA) Class III/IV], 28% had ≥moderate MR and 14% had ≥moderate TR. Over median 7.1 months, 171 (75%) patients with ≥moderate MR and 87 (75%) of patients with ≥moderate TR experienced regression to no/mild MR and TR, respectively. Conversely, over median 13 months, incident ≥moderate MR and TR developed in 5% and 6%, respectively, of patients with no/mild baseline MR and TR. Number of GDMT medications at follow-up was less in patients who did not have MR/TR regression (vs who did) and in patients who developed MR/TR (vs who did not). Patients with NYHA Class I/II received a similar number of GDMT and had a similar rate of MR and TR regression and development vs patients with NYHA Class III/IV. However, patients with mildly reduced EF received less GDMT medications vs patients with moderately reduced EF and experienced less MR regression. Conclusion In patients with a recent diagnosis of HFrEF receiving contemporary GDMT, the majority with ≥moderate secondary MR and TR achieved regression of MR/TR, and the minority without significant baseline MR/TR developed ≥moderate regurgitation at follow-up.
Telomere length as a marker of biological age in paediatric multiple sclerosis
Jacques, Kayla , Race, Jonathan , Goyne, Christopher, Fair, Ashley, Schuette, Allison, Yang, Jennifer H. , Caillier, Stacy J. , Aaen, Gregory Scott, Abrams, Aaron , Benson, Leslie, Casper, T Charles, Chitnis, Tanuja, Gorman, Mark , Lotze, Tim, Mar, Soe , Ness, Jayne , Rose, John W. , Schreiner, Teri , Tillema, Jan-Mendelt , Waldman, Amy T, Wheeler, Yolanda , Oksenberg, Jorge, Lin, Jue , Waubant, Emmanuelle, Aaen, Gregory S , Krupp, Lauren , Wheeler, Yolanda S , Yang, Jennifer H , Aaen, Gregory , Benson, Leslie , Casper, T. Charles , Chitnis, Tanuja , Rensel, Mary R. , Rodriguez, Moses , Schreiner, Teri , Tillema, Jan‐Mendelt , Waldman, Amy , Oksenberg, Jorge R. , Waubant, Emmanuelle L. , Graves, Jennifer

Mayo Clinic

Journal of Neurology, Neurosurgery & Psychiatry | February 17, 2026 | Volume: 97 | Issue: 4 | Pages: 302-308

10.1136/jnnp-2025-336736 | PMID 41500800 Get It

Background Increased chronological age correlates with reduced relapse rates and increased disability in multiple sclerosis (MS). Biological age may better capture ageing’s impact on MS and might accelerate due to MS itself. Establishing accelerated biological ageing in adults is complicated by normal ageing and comorbidities. Telomere length, a well-recognised biological ageing marker, is shortened in adults with MS and associated with disability. Demonstrating accelerated biological ageing in paediatric-onset MS (POMS) would strengthen the hypothesis that MS drives premature biological ageing. This study aimed to determine if telomere length differs in POMS compared to age-similar healthy controls. Methods We performed a cross-sectional case-control study of whole blood samples and clinical data from The US Network of Pediatric MS Centers. Real-time quantitative PCR measured telomere length, expressed as a telomere to somatic DNA ratio (T/S ratio). T/S ratio was compared between cases and age-similar healthy controls using multivariate regression analysis adjusting for chronological age, sex, race, ethnicity, tobacco exposure, socioeconomic status and body mass index. Results We analysed 300 POMS cases and 200 controls. The unadjusted mean T/S ratios were 1.66 (SD 0.32) for cases and 1.71 (SD 0.29) for controls (mean difference –0.05, 95% CI –0.10 to 0.01, p=0.08). After adjusting for key covariables with face validity, POMS participants had a mean 0.086 shorter T/S ratio than controls (95% CI 0.015 to 0.157, p=0.018). Conclusions POMS participants demonstrated shorter telomeres than age-similar controls in a multivariable model adjusting for sociodemographic variables, suggesting that MS may contribute to accelerated biological ageing.
Abstract PD4-02: An AI algorithm for breast cancer detection improves future BC risk prediction among women with benign breast disease
Vachon, C. M., Winham, S., Jensen, M., Hursh, D., Norman, A., Fischer, Jessica, Schrup, S., Seymour, L., Gehling, Denice, Nyante, S., Troester, M. A., Karssemeijer, Nico , Vierkant, R., Radisky, D., Scott, C., Maimone, S. I., Degnim, Amy C., Sherman, M. E., Jensen, Michael A. , Pacheco-Spann, Laura M. , Norman, Aaron D. , Seymour, Lisa R. , Nyante, Sarah J. , Vierkant, Robert A. , Radisky, Derek C. , Maimone, Santo , Degnim, Amy C. , Sherman, Mark E.

Mayo Clinic

Clinical Cancer Research | February 17, 2026 | Volume: 32 | Issue: 4_Supplement | Pages: PD4-02-PD4-02

10.1158/1557-3265.sabcs25-pd4-02 Get It

Abstract Background: Artificial intelligence (AI) algorithms based on deep learning approaches show promise in improving breast cancer (BC) detection on mammography and may also improve prediction of future BC risk compared with clinical risk prediction models. Historical clinical risk prediction models underperform among women with BBD; however, AI models for BC detection on mammography have not been tested among women at elevated BC risk due to benign breast disease (BBD). We evaluated if an AI cancer detection algorithm can aid BC risk prediction among women with BBD. Methods: We examined women without a prior BC who had an initial BBD biopsy at Mayo Clinic, Rochester, between 2002 and 2013. Incident BC occurring after BBD was identified using the Mayo Tumor Registry and supplemented by follow-up questionnaires. Only women with a full field digital mammogram at least 2 years prior to BC diagnosis were eligible. A breast pathologist evaluated BBD according to increasing severity, as non-proliferative (NP), proliferative disease without atypia (PDWA) or atypical hyperplasia (AH). AI malignancy scores derived from the Transpara detection algorithm (1-10) and volumetric percent density (VPD) from Volpara (per one standard deviation, SD) were assessed from mammograms close to BBD diagnosis. Cox proportional hazards regression models were applied to estimate hazard ratios (HRs) with 95% Confidence Intervals (CIs), adjusted for age and BMI. C-statistics were estimated to assess the contribution of each factor to BC risk prediction. Likelihood ratio tests (LRTs) and bootstrapping methods were used to compare model performance with the addition of AI malignancy score. Results: The BBD cohort with mammography consisted of 3,125 women followed for a median 12.9 years, with 250 incident BC. Of these, 221 BC occurred at least two years after the mammogram and were used in analyses. As expected, increased BC risk was associated with BBD severity [for AH HR=3.18 (95%CI: 2.04, 4.95) and for PDWA HR=1.59 (95%CI: 1.17, 2.14) compared to NP] and with higher VPD [HR=1.24 per SD (95% CI: 1.05, 1.45)] (Table ). The AI-malignancy score alone was also associated with BC risk [HR=1.16 per 1 unit score (95%CI: 1.09,1.23)] and showed similar discriminatory accuracy [C-statistic=0.626 (95%CI: 0.586, 0.665)] as the model with BBD severity and VPD combined [C-statistic=0.627, (95%CI: 0.585, 0.669)] (Table ). In models with BBD severity and VPD, the AI-malignancy score was an independent risk factor for BC [HR=1.14 (95%CI: 1.07, 1.21); PLRT&lt;0.001] but only achieved a marginally significant improvement in discriminatory accuracy [C-statistic=0.651 (0.609, 0.693), ΔC-statistic=0.024 (95% CI: 0.000, 0.047)]. Conclusion: In this preliminary study, an AI BC detection algorithm achieved similar performance in predicting future BC risk compared to established risk factors. Citation Format: C. M. Vachon, S. Winham, M. Jensen, D. Hursh, L. Pacheco-Spann, A. Norman, J. Fischer, S. Schrup, L. Seymour, D. Gehling, S. Nyante, M. Troester, N. Karssemeijer, R. Vierkant, D. Radisky, C. Scott, S. I. Maimone, A. Degnim, M. Sherman. An AI algorithm for breast cancer detection improves future BC risk prediction among women with benign breast disease [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PD4-02.
Shape-sensing robotic-assisted bronchoscopy with integrated mobile cone-beam CT for small nodules: results from the prospective multicentre CONFIRM study
Husta, Bryan C, Cheng, George Z. , Batra, Hitesh , Reisenauer, J., Bartek, William, Kalchiem‐Dekel, Or , Zouk, Aline, Patel, Niral, Chawla, Mohit, Eapen, George A. , Jiménez, C. Delgado, Lee, R. J., Bott, Matthew J. , Oh, Scott , Casal, Roberto F, Casal, Roberto , Reisenauer, Janani , Zouk, Aline N., Patel, Niral M. , Chawla, Mohit , Casal, Roberto F.

Mayo Clinic

Thorax | February 16, 2026 | Volume: 81 | Issue: 3 | Pages: 267-275

10.1136/thorax-2025-223272 | PMID 41698810 Get It

Background The use of 3D imaging with navigation bronchoscopy has increased with the introduction of mobile cone-beam CT (mCBCT). Shape-sensing robotic-assisted bronchoscopy (ssRAB) integrated with mCBCT has been introduced to correct for CT to body divergence (CT-BD) during the biopsy of peripheral pulmonary nodules (PPNs). Methods Prospective observational multicentre study, enrolling patients with a PPN of ≤20 mm suspicious for malignancy, assessing tool-in-lesion (TIL), diagnostic yield, sensitivity for malignancy and incidence of pneumothorax or airway bleeding. Non-malignant index biopsies were followed for 12 months. Descriptive statistics are reported for all variables along with 95% CI for primary endpoints. Results 155 consecutive patients were enrolled at six centres. Median nodule size was 14.0 mm (IQR 11.0–17.0), with 54.8% of nodules (85/155) in the upper lobes, 25.8% (40/155) with CT bronchus sign present and median distance to the nearest pleural surface of 8.2 mm (IQR 1.8–20.0). TIL was achieved in 154/155 (99.4%, 95% CI 96.5 to 100.0) procedures. A median of two (IQR 1–3) mCBCT spins were performed, with median dose area product of 25.7 Gy · cm 2 (IQR 11.0–46.7). Diagnostic yield per the American Thoracic Society/American College of Chest Physicians (ATC/ACCP) definition was 89.0% (n=138/155; 95% CI 83.0 to 93.5) and sensitivity for malignancy was 91.5% (95% CI 86.4 to 96.5). No pneumothorax (0%, 95% CI 0.0 to 2.4) and two Nashville Grade three bleeding events were reported (1.3%, 95% CI 0.2 to 4.6). Interpretation The first prospective multicentre study of integrated ssRAB and mCBCT for small peripheral nodules resulted in diagnostic outcomes similar to those reported for transthoracic biopsy with a more favourable safety profile. Trial registration number ClinicalTrials.gov ID: NCT05562895 .